Komori
Earnings7707Precision System Science Co.,Ltd.Electrical equipment and precision instruments

Summary of Financial Results for the Fiscal Year Ended June 2025 [Japanese GAAP] (Consolidated)

Net sales increased 17.9% year on year, and operating, ordinary and net losses all narrowed substantially, although the company remained in the red. For the next fiscal year, the company expects operating income to turn profitable at ¥114 million, while the year-end dividend remains undetermined.

Worth reading
57In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
17.9
% (year-on-year change in revenue)
Wording
Conditional
How definitive the wording is.

Results for this period

Full year1 July 2024 to 30 June 2025ConsolidatedJapanese GAAP
Net Sales4,692¥ millionYear on year +17.9%Progress 94.9%
Operating profit-121¥ million
Ordinary income-139¥ million
Net income attributable to owners of the parent-253¥ million

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.

Net income per share△9.21円
Operating Margin△2.6％
Financial position at period-end
Total assets4,937¥ million
of which net assets 3,760 ¥ millionEquity ratio 76.2%vs. prior year-end +11.4pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Cash inflows and outflows
Operating+95
Investment-8
Financials-910
Net change-823

Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.

Cash and cash equivalents at end of period¥1,036 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥4,942 million (YoY +5.3%)
Operating profit¥114 million
Ordinary income¥89 million
Net income¥77 million
Annual Dividend Forecast¥0.00 → Undecided（Undecided）
Factors Behind Changes in Business Performance

臨床診断装置の堅調な推移と装置売上増に伴う試薬・消耗品、メンテナンス関連製品の伸長、抜本的な事業再編・費用抑制による販売費及び一般管理費の減少

Disclosure regarding the going concern assumption

継続企業の前提に重要な疑義を生じさせる事象又は状況は存在するが、重要な不確実性は認められないと判断。継続企業の前提に関する注記は「該当事項はありません」

Change in accounting policy
基準改正に伴う変更 Yesそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 companies / Excluded 1社（ユニバーサル・バイオ・リサーチ株式会社） / Removal from the scope of equity-method accounting 1社（株式会社 PF・BioLine）
Material subsequent eventsNo applicable matters.
Impairment lossNone recorded for the fiscal year (impairment loss is shown as "－" on the consolidated income statement)
Breakdown of extraordinary income (loss)Extraordinary income Item Gain on Sale of Fixed Assets / Amount ¥0 thousand, Item Gain on sale of shares in an affiliated company / Amount ¥8,987 thousand, Item Other / Amount ¥441 thousand, Item Total extraordinary income / Amount ¥9,429 thousand / Extraordinary loss Item Loss on sale of fixed assets / Amount ¥1,031 thousand, Item Loss on disposal of property, plant and equipment / Amount ¥4,139 thousand, Item Business-structure improvement costs / Amount ¥59,489 thousand, Item Compensation for damages / Amount ¥54,012 thousand, Item Other / Amount ¥0 thousand, Item Total extraordinary loss / Amount ¥118,673 thousand
Depreciation and amortization¥238,106 thousand
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingYes (for institutional investors)
Issued Shares at Period-End27,666,900
Treasury Shares at Period-End476,128
Results for this period
ItemDetails
Fiscal Period ClassificationFull year
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedConsolidated
Period Covered1 July 2024 to 30 June 2025
Net Sales¥4,692 million (YoY +17.9%)
Operating profit¥-121 million
Ordinary income¥-139 million
Profit attributable to owners of the parent¥-253 million
Net income per share△9.21円
Operating Margin△2.6％
Equity ratioEnd of the current fiscal period 76.2％ / End of previous period 64.8％
Total assets¥4,937 million
Net assets¥3,760 million
Cash flows from operating activities¥95 million
Cash flows from investing activities¥-8 million
Cash flows from financing activities¥-910 million
Cash and cash equivalents at end of period¥1,036 million
Full-year earnings forecastNet Sales ¥4,942 million (YoY +5.3%) / Operating profit ¥114 million / Ordinary income ¥89 million / Net income ¥77 million
Annual Dividend Forecast¥0.00 → Undecided（Undecided）
Depreciation and amortization¥238,106 thousand
Impairment lossNone recorded for the fiscal year (impairment loss is shown as "－" on the consolidated income statement)
Breakdown of extraordinary income (loss)Extraordinary income Item Gain on Sale of Fixed Assets / Amount ¥0 thousand, Item Gain on sale of shares in an affiliated company / Amount ¥8,987 thousand, Item Other / Amount ¥441 thousand, Item Total extraordinary income / Amount ¥9,429 thousand / Extraordinary loss Item Loss on sale of fixed assets / Amount ¥1,031 thousand, Item Loss on disposal of property, plant and equipment / Amount ¥4,139 thousand, Item Business-structure improvement costs / Amount ¥59,489 thousand, Item Compensation for damages / Amount ¥54,012 thousand, Item Other / Amount ¥0 thousand, Item Total extraordinary loss / Amount ¥118,673 thousand
Disclosure regarding the going concern assumption継続企業の前提に重要な疑義を生じさせる事象又は状況は存在するが、重要な不確実性は認められないと判断。継続企業の前提に関する注記は「該当事項はありません」
Change in accounting policyChanges due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement No
Changes in the scope of consolidationNew 0 companies / Excluded 1社（ユニバーサル・バイオ・リサーチ株式会社） / Removal from the scope of equity-method accounting 1社（株式会社 PF・BioLine）
Material subsequent eventsNo applicable matters.
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingYes (for institutional investors)
Issued Shares at Period-End27,666,900
Treasury Shares at Period-End476,128
Factors Behind Changes in Business Performance臨床診断装置の堅調な推移と装置売上増に伴う試薬・消耗品、メンテナンス関連製品の伸長、抜本的な事業再編・費用抑制による販売費及び一般管理費の減少
Items this document does not state (7)
Revision to Earnings ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlog

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

臨床診断装置が堅調に推移し、装置の売上増加に伴って核酸抽出試薬・関連消耗品・メンテナンス関連製品の売上が伸長しました。また、海外連結子会社及び合弁会社の解散を含む抜本的な事業再編と費用抑制施策により、販売費及び一般管理費が減少しました。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Summary of Financial Results for the Fiscal Year Ended June 2025 [Japanese GAAP] (Consolidated) | Precision System Science Co.,Ltd. (7707) timely disclosure | Komori